Tag: CohBar
November 6, 2019
8 Anti-aging Stocks in the US
It can be tough to find public anti-aging companies to invest in, but it's certainly possible with a little time... November 6, 2019
CohBar Completes Phase 1a and Initiates Phase 1b Stage of Clinical Trial of CB4211 Under Development for NASH and Obesity
CohBar announced the completion of the Phase 1a stage of the ongoing Phase 1a/1b study evaluating the safety, tolerability, and... May 3, 2019
CohBar to Resume its Phase 1a/1b Clinical Trial
CohBar (NASDAQ:CWBR) has announced it will be resuming its Phase 1a/1b clinical trial of CB4211 after concluding conversations with the...
December 2, 2018
5 Top Weekly NASDAQ Biotech Stocks: Arsanis Gains 271 Percent
Arsanis, Tyme Technologies, CohBar, Cocrystal Pharma and Contrafect were last week's top gainers. July 12, 2018
CohBar Initiates Clinical Study with First-in-human Dosing of CB4211, a Novel Mitochondria Based Therapeutic for the Treatment of NASH
CohBar (NASDAQ:CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics (MBTs) to treat age-related diseases, today announced that it... April 19, 2018
CohBar Announces Voluntary Delisting from the TSX Venture Exchange
CohBar (NASDAQ:CWBR) and (TSXV:COB.U) today announced that it has applied to voluntarily delist its common shares from the TSX Venture...
April 13, 2017